Tue, May 10, 5:34 PM
Tue, Mar. 29, 5:39 PM
Jun. 25, 2015, 11:26 AM
- Immunovaccine (OTCQX:IMMVF) and Incyte (INCY -0.5%) enter into a non-exclusive clinical trial collaboration to evaluate the combination of Immunovaccine's DPX-Survivac, Incyte's epacadostat and cyclophosphamide in platinum-resistant ovarian cancer patients who are at high risk of recurrence. The Phase 1b study will enroll ~20 subjects. Financial terms are not disclosed.
- DPX-Survivac is a therapeutic vaccine candidate that contains survivin-based peptide antigens formulated in its DepoVax adjuvanting platform. It is designed to train the immune system to generate robust CD8 T cells against survivin, a protein expressed in most cancer cells that inhibits apoptosis (programmed cell death).
- Epacadostat is a small molecule inhibitor of IDO1, an immunosuppressive enzyme that has been shown to induce regulatory T cell generation and activation thereby allowing cancer cells to avoid detection by the immune system.
Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company's DeopVax platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation... More
Other News & PR